



## **Vedolizumab (Entyvio®) Infusion Price Quote**

### ***About Entyvio®***

Entyvio® is an anti-inflammatory drug administered via intravenous (IV) infusion by a health care professional. Entyvio® has been proven to reduce the signs and symptoms of moderate to severe ulcerative colitis (UC) and moderate to severe Crohn's disease (CD) when certain other medicines have not worked well enough or cannot be tolerated.

Entyvio® can also reduce the signs and symptoms, induce and maintain remission, promote intestinal healing and reduce or stop the need for corticosteroids. Ulcerative colitis and Crohn's disease are serious and chronic diseases. While Entyvio® will not cure them, it is proven to help many people gain control over their symptoms.

### ***Billing***

Listed below are the specific billing codes and associated fees for Entyvio® infusions.

After you and your MNGI provider decide to begin Entyvio® treatment, MNGI will partner with you in enrolling in any financial assistance programs for which you may be eligible.

The actual allowed amount (the amount of the billed charge deemed payable by an insurance plan) for each charge and the amount of your out-of-pocket expenses will depend on your particular insurance plan. Although MNGI can help you to determine insurance coverage for Entyvio® treatment, it is important to direct any additional questions you may have regarding coverage and your financial responsibility to your insurer prior to receiving treatment.

If you have any further questions, please contact the Business Office at 612-871-1145.

<b>Billing Code (CPT Code)</b>	<b>Description</b>	<b>Charge Amount</b>
J3380	Entyvio® (vedolizumab)	\$9,600
96365	IV Infusion administration charge	\$254

***Prices may be subject to change***